SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Trading update

12 Jan 2022 07:00

RNS Number : 1353Y
Frontier IP Group plc
12 January 2022
 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

RNS

AIM: FIPP

12 January 2022

 

 

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

Trading update

 

Frontier IP (AIM: FIPP), a specialist in commercialising intellectual property, is today providing a trading update ahead of publication of its interim results for the six months to 31 December 2021 ("H1 2022") which are expected to be released in March 2022. The Group has enjoyed a strong first half to the financial year in particular due to the IPO on the Nasdaq Global Select Market of portfolio company Exscientia plc ("Exscientia") during the period.

 

Exscientia reported a strong set of quarterly results post admission and, on 7 January 2022, announced a strategic research collaboration with Sanofi that will entitle Exscientia to an upfront cash payment of $100 million with the potential for $5.2 billion in total milestones plus tiered royalties. The uplift in book value of this holding as at 31 December 2021 is expected to make a significant contribution to the performance of the Group in H1 2022.

Further to the release of the Group's full year results in October 2021, Frontier IP has now commenced a programme to realise part of its shareholding in Exscientia. As at the date of this announcement a small portion has been sold in January 2022 and the Group will provide a further update at the appropriate time.

The Group's portfolio as a whole has continued to show strong commercial and technical progress and a number of the companies are reaching key inflection points. During the period The Vaccine Group announced encouraging data on the development of its next generation COVID-19 vaccine, Camgraphic completed a fundraising and management was strengthened at Pulsiv. This momentum is continuing into 2022 and yesterday we were pleased to note Celerum launching its Truck Logistics System at a time when supply chain challenges are high on the priority list for many businesses.

 

While it is clear there are many challenges facing markets and industry, we anticipate reporting a set of results for H1 2022 ahead of management expectations and continuing to build on progress in the balance of the financial year. We remain confident on the Group's prospects for the remainder of the financial year and beyond.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORRURUAAUR
Date   Source Headline
17th Mar 20203:15 pmRNSNotice of interim results
13th Mar 20207:00 amRNSPortfolio news – The Vaccine Group Update
12th Mar 202011:05 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
19th Feb 202012:37 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSCRIL wins EUR140,000 EU Graphene Flagship funding
12th Feb 20207:00 amRNSPortfolio news - FIPP increases stake in Celerum
31st Jan 20207:00 amRNSPortfolio news - Exscientia
20th Jan 20207:00 amRNSPortfolio news - The Vaccine Group raises £680,000
16th Jan 20203:28 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSFieldwork Robotics secures first equity funding
10th Jan 20207:00 amRNSExscientia enters collaboration with Bayer AG
31st Dec 20191:00 pmRNSTotal Voting Rights
16th Dec 201910:36 amRNSExercise of Options and Issue of Equity
11th Dec 20196:03 pmRNSHolding(s) in Company
9th Dec 20193:25 pmRNSHolding(s) in Company
9th Dec 20193:21 pmRNSHolding(s) in Company
9th Dec 20192:08 pmRNSHolding(s) in Company
9th Dec 20199:46 amRNSHolding(s) in Company
9th Dec 20197:00 amRNSGrant of Options
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.